Zacks Research Weighs in on Kodiak Sciences Q1 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities research analysts at Zacks Research issued their Q1 2027 EPS estimates for Kodiak Sciences in a research note issued on Wednesday, April 16th. Zacks Research analyst R. Department expects that the company will post earnings per share of ($0.91) for the quarter. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Zacks Research also issued estimates for Kodiak Sciences' FY2027 earnings at ($3.49) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.06.

Separately, HC Wainwright restated a "neutral" rating and set a $3.00 price target on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Stock Up 13.5 %

KOD traded up $0.49 during trading on Friday, hitting $4.13. 607,777 shares of the company traded hands, compared to its average volume of 342,526. The firm has a market cap of $217.85 million, a P/E ratio of -1.13 and a beta of 2.40. Kodiak Sciences has a one year low of $1.92 and a one year high of $11.60. The stock's fifty day moving average is $3.34 and its 200 day moving average is $5.39.

Institutional Trading of Kodiak Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its position in shares of Kodiak Sciences by 10,982.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company's stock worth $12,622,000 after acquiring an additional 1,257,063 shares in the last quarter. TCG Crossover Management LLC lifted its holdings in Kodiak Sciences by 13.6% during the 4th quarter. TCG Crossover Management LLC now owns 1,145,538 shares of the company's stock worth $11,398,000 after purchasing an additional 137,380 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Kodiak Sciences in the 4th quarter worth about $11,338,000. Silverarc Capital Management LLC grew its holdings in Kodiak Sciences by 100.0% during the 4th quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company's stock valued at $9,950,000 after buying an additional 500,000 shares in the last quarter. Finally, Boxer Capital Management LLC bought a new stake in shares of Kodiak Sciences during the fourth quarter valued at about $9,950,000. Institutional investors own 89.06% of the company's stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.